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the effect of different clinical forms of AF on plasma concentration of Von
Willebrand Factor (vWF) at different levels of circulatory tree, both intracar-
diac and extracardiac.
Methods and results: Peripheral (Pf), left atrial (LA), and coronary sinus
(CS) blood samples were obtained during cardiac catheterization from
52 patients with paroxysmal AF (PAF), 36 with persistent AF (PsAF), and 17
control subjects (Ct) with Wolff-Parkinson-White syndrome. Plasma levels of
VEGF and vWF were measured at the three sampled sites. Peripheral VEGF
levels were higher in both PAF and PsAF patients than in controls (P≤0.03).
Left atrial VEGF levels were higher in paroxysmal AF (P=0.05), but not in
persistent AF (P=0.32), compared with controls. Coronary sinus and pulmo-
nary vein VEGF levels did not differ significantly among groups. Compared
with Ct, patients with PAF had higher LA plasma levels of vWF (P=0.004),
but similar Pf and CS levels (both P>0.30). In contrast, patients with PsAF
had higher plasma concentrations of vWF in Pf (P=0.04), LA (P<0.001), and
CS (P=0.04) samples compared with Ct. Left atrial plasma concentrations of
vWF in patients with PsAF were also higher than in the PAF group (P=0.04).
Conclusion: This study suggests that inflammatory process in AF is of low
grade. The heart itself is the most likely source of high left atrial VEGF; how-
ever, this disorder appears to be a transient event in AF history. AF patients
presented significantly higher plasma concentrations of vWF. This study sug-
gests an association between the clinical evolution of AF and the progression
of endothelial dysfunction. Further studies will have to establish the exact
mechanisms that link endothelial dysfunction and stroke in the context of AF.
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Effect of smoking on comparative efficacy of antithrombotic therapy
in patients with atrial fibrillation. A community based cohort study
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Smoking is incorporated in a simple score (SAMe-TT2R2) that can predict
poor INR control in patients with atrial fibrillation (AF) treated with vitamin K
antagonists (VKA). Moreover, the clinical benefit of clopidogrel in reducing myo-
cardial infarction and stroke in randomized clinical trials of antiplatelet drugs
(APD) was seen primarily in smokers, with little benefit in nonsmokers. We made
the hypothesis that active smoking may differently influence 1) the risk of stroke
and 2) the risk of bleeding in AF patients treated with VKA or with APD.
Methods: We examined the clinical course of 7.948 consecutive patients
with AF and/or atrial flutter seen between 2000-2010. The outcomes in
patients with active smoking were compared with those in other patients.
Results: Among 7.948 patients with AF (age 71±15 years), 1034 (13%) had
active smoking. APD was prescribed on an individual basis for 2761 patients
(35%) and VKA for 4534 (57%). During a follow-up of 929±1082 days, 631
strokes/thromboembolic events, 707 severe bleedings and 248 major BARC
bleedings were recorded. Smoking was not independently associated with a higher
risk of stroke in these AF patients (relative risk=0.94, 95% CI 0.75-1.18, p=0.62).
By contrast, after adjustment on age, CHADS2 score, HASBLED bleeding risk
score, VKA use and APD use, smoking was independently associated with a
worse prognosis for the risk of severe bleeding (relative risk=1.23, 95% CI 1,02-
1,50, p=0.03) and for the risk of major BARC bleeding (relative risk=1.40, 95%
CI 1.03-1.91, p=0.03). Smoking was independently associated with a higher risk
of bleeding in patients treated with VKA (relative risk= 1.32, 95% CI 1.04-1.66.
p=0.02) whilst this association did not reach significance in patients treated with
APD (relative risk=1.31, 95% CI 0.97-1.76. p=0.07).
Conclusion: In AF, there was a higher risk of bleeding in smokers, mainly
in those treated with VKA
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Aims: This study aimed to assess the effectiveness and safety of switching
from Prasugrel to Ticagrelor patients identified as Prasugrel low-responders
one month after ACS.
Methods and results: 540 patients admitted for ACS with coronary stent
implantation and discharged on Prasugrel 10mg were screened. Prasugrel
response was assessed one month after discharge using Platelet Reactivity
Index Vasodilatator Stimulated Phosphoprotein (PRI VASP). High on-Treat-
ment Platelet Reactivity (HTPR) was defined as VASP>50%. Patients with
HTPR were enrolled and switched to Ticagrelor 90 mg twice a day. They
were re-tested a month later. Primary endpoint was defined as: comparison of
degree of platelet inhibition and incidence of HTPR one month after switching
to Ticagrelor in patients with HTPR on Prasugrel therapy. The safety endpoint
was the incidence of bleedings under Ticagrelor as compared with Prasugrel
therapy, using the Bleeding Academic Research Consensus definition.
Between March 2010 and November 2013, 19 patients were defined as
HTPR on Prasugrel 10 mg one month after ACS, with a mean VASP of
59,3%. Among these patients, 14 were switched to Ticagrelor 180 mg daily
and, at one month, we observed a significant decrease in PRI VASP, with a
mean value at 19.6% (p<0.001). No patients remained HTPR and 4 patients
(28.4%) were identified as Very Low on-Treatment Platelet Reactivity
(VLTPR) (VASP<10%). No ischemic events were reported after switching,
while 3 patients (21%) suffered from bleeding complications (2 BARC1 and
1 BARC2 bleedings) during Ticagrelor therapy.
Conclusion: Switch to Ticagrelor in Prasugrel’s “low responders” patients is
an effective strategy, leading to an adequate platelet inhibition in a large majority
of patients. This biological tailored approach could be useful in preventing isch-
emic complications, in this specific high risk population, potentially increasing
bleeding risk. This hypothesis needs to be confirmed in large clinical studies.
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[ * : P<0.05 vs control:** : P<0.05 vs paroxysmal AF, using the unpaired t-test ]
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